Canaccord weighs in on Edwards Lifesciences (EW +11.3%) after a stellar Q1 result, recommending...


Canaccord weighs in on Edwards Lifesciences (EW +11.3%) after a stellar Q1 result, recommending investors buy the shares ahead of a few catalysts, including an NCD final decision expected in early May and a Cohort-A Panel in mid-June.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs